培:更新审查其在高血压中使用。

文章的细节

引用

复制到剪贴板

赫斯特米,贾维斯B

培:更新审查其在高血压中使用。

药。2001;61 (6):867 - 96。

PubMed ID

11398915 (在PubMed

]

文摘

培erbumine(培)是一种前体药物perindoprilat酯,一种血管紧张素转换酶(ACE)抑制剂。培4到8毫克,每日一次,大大降低仰卧的收缩压(SBP)、舒张压(菲律宾)在高血压患者基线值。这些削减是保持了至少24小时,就是明证槽/峰值率> 50%。血管异常与高血压相关的改善或正常化在培治疗。培4到8毫克,每日一次,显著降低carotid-femoral主动脉脉搏波速度(采集),改善动脉合规、左心室质量指数,降低性脑缺血患者的近期和/或中风,脑血流量保存尽管显著减少SBP和菲律宾。还需要进一步的研究来建立的意义有前景的结果显示,减少主动脉采集相关终末期肾功能衰竭患者的死亡率下降,其中三分之一收到培。反应率(数量的患者仰卧位<类似或= 90毫米汞柱)显著高于培4到8毫克每天一次(67 - 80%)与卡托普利25到50毫克每天两次(44 - 57%)3随机双盲试验。在其他临床试验,培的抗高血压作用类似于其他血管紧张素转换酶抑制剂(包括卡托普利)和钙通道拮抗剂。联合治疗联合培和一个来自另一个治疗的抗高血压药类提供额外的好处,要么作为一线治疗或未能应对单一疗法的病人。培单一疗法也是有效的老年人和高血压患者和伴随疾病。 Perindopril has a similar adverse event profile to that of other ACE inhibitors; cough is the most common event reported during treatment, and is also the most common adverse event responsible for treatment withdrawal. CONCLUSIONS: Perindopril is a well tolerated ACE inhibitor that is significantly better than captopril (in terms of response rates) in the treatment of hypertension, and as effective as other ACE inhibitors. Perindopril appears to reverse some of the vascular abnormalities associated with hypertension, including arterial stiffness and left ventricular hypertrophy, although further research is needed to confirm promising results regarding its ability to decrease associated cardiovascular morbidity and mortality. Results from ongoing studies will help confirm the place of perindopril in the treatment of hypertension; currently, it is an effective and well tolerated treatment for patients with mild to moderate essential hypertension.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

联合培